RCUS · Insider Trading
Arcus Biosciences, Inc.
Every open-market purchase and sale reported by RCUS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-24 | Alexander Azoy | Chief Accounting Officer | MIXED | — | −$41.16K |
| 2026-07-13 | Juan C. Jaen | President | Sell | −68,569 | −$2.03M |
| 2026-06-24 | Juan C. Jaen | President | Sell | −31,431 | −$877.50K |
| 2026-06-12 | David L. Lacey | Director | A | +5,700 | — |
| 2026-06-12 | Carolyn C. Tang | General Counsel | M | +34,090 | +$87.75K |
| 2026-06-12 | Antoni Ribas | Director | A | +5,700 | — |
| 2026-06-12 | Kathryn E Falberg | Director | A | +5,700 | — |
| 2026-06-12 | Patrick Machado | Director | A | +5,700 | — |
| 2026-06-12 | Nicole Lambert | Director | A | +5,700 | — |
| 2026-06-12 | Yasunori Kaneko | Director | A | +5,700 | — |
| 2026-06-12 | Andrew J Perlman | Director | A | +5,700 | — |
| 2026-06-01 | Alexander Azoy | Chief Accounting Officer | Sell | −2,562 | −$66.02K |
| 2026-05-12 | II Robert C. Goeltz | Chief Financial Officer | Sell | −7,763 | −$198.97K |
| 2026-05-12 | Antoni Ribas | Director | G | −5,050 | — |
| 2026-01-26 | II Robert C. Goeltz | Chief Financial Officer | A | +24,000 | — |
| 2026-01-26 | Richard Markus | Chief Medical Officer | A | +24,000 | — |
| 2026-01-26 | Jennifer Jarrett | Chief Operating Officer | A | +31,000 | — |
| 2026-01-26 | Carolyn C. Tang | General Counsel | A | +24,000 | — |
| 2026-01-26 | Alexander Azoy | Chief Accounting Officer | A | +21,050 | — |
| 2026-01-26 | Juan C. Jaen | President | A | +31,000 | — |
| 2026-01-26 | Terry J Rosen | Chief Executive Officer | A | +79,000 | — |
| 2026-01-09 | Terry J Rosen | Chief Executive Officer | G | −35,000 | — |
| 2026-01-07 | Juan C. Jaen | President | Sell | −31,823 | −$681.34K |
| 2026-01-02 | Terry J Rosen | Chief Executive Officer | G | −2,400 | — |
| 2026-01-02 | II Robert C. Goeltz | Chief Financial Officer | Sell | −6,552 | −$153.19K |
| 2025-12-18 | Richard Markus | Chief Medical Officer | Sell | −9,546 | −$210.14K |
| 2025-12-18 | Carolyn C. Tang | General Counsel | Sell | −14,468 | −$318.50K |
| 2025-12-18 | II Robert C. Goeltz | Chief Financial Officer | Sell | −12,662 | −$278.74K |
| 2025-12-18 | Terry J Rosen | Chief Executive Officer | Sell | −54,691 | −$1.20M |
| 2025-12-18 | Alexander Azoy | Chief Accounting Officer | Sell | −8,832 | −$195.43K |
| 2025-12-18 | Jennifer Jarrett | Chief Operating Officer | Sell | −21,208 | −$466.87K |
| 2025-12-18 | Juan C. Jaen | President | Sell | −21,208 | −$466.87K |
| 2025-12-05 | Juan C. Jaen | President | Sell | −82,997 | −$2.05M |
| 2025-12-01 | Alexander Azoy | Chief Accounting Officer | MIXED | — | −$24.07K |
| 2025-11-26 | II Robert C. Goeltz | Chief Financial Officer | Sell | −5,000 | −$125.00K |
| 2025-11-19 | Juan C. Jaen | President | Sell | −50,000 | −$1.01M |
| 2025-11-12 | Jennifer Jarrett | Chief Operating Officer | MIXED | — | −$892.33K |
| 2025-11-03 | Juan C. Jaen | President | Sell | −4,314 | −$87.65K |
| 2025-10-30 | Juan C. Jaen | President | Sell | −96,859 | −$2.01M |
| 2025-10-29 | II Robert C. Goeltz | Chief Financial Officer | Sell | −5,000 | −$100.00K |
| 2025-10-08 | Jennifer Jarrett | Chief Operating Officer | MIXED | — | −$688.67K |
| 2025-09-30 | Alexander Azoy | Chief Accounting Officer | Sell | −2,831 | −$36.80K |
| 2025-09-05 | Alexander Azoy | Chief Accounting Officer | Sell | −1,579 | −$18.76K |
| 2025-06-12 | Nicole Lambert | Director | A | +13,300 | — |
| 2025-06-12 | Kathryn E Falberg | Director | A | +13,300 | — |
| 2025-06-12 | Patrick Machado | Director | A | +13,300 | — |
| 2025-06-12 | Antoni Ribas | Director | A | +13,300 | — |
| 2025-06-12 | David L. Lacey | Director | A | +13,300 | — |
| 2025-06-12 | Yasunori Kaneko | Director | A | +13,300 | — |
| 2025-06-12 | Andrew J Perlman | Director | A | +13,300 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| GILEAD SCIENCES, INC. | 10%+ Owner | 31,424,760 | $558.10M |
| Terry J Rosen | Chief Executive Officer | 5,670,279 | $100.70M |
| Juan C. Jaen | President | 1,200,799 | $21.33M |
| Yasunori Kaneko | Director | 530,750 | $9.43M |
| Jennifer Jarrett | Chief Operating Officer | 224,024 | $3.98M |
| Carolyn C. Tang | General Counsel | 184,607 | $3.28M |
| Kathryn E Falberg | Director | 176,406 | $3.13M |
| Richard Markus | Chief Medical Officer | 89,647 | $1.59M |
| Dimitry SA Nuyten | Chief Medical Officer | 87,518 | $1.55M |
| II Robert C. Goeltz | Chief Financial Officer | 84,161 | $1.49M |
| David L. Lacey | Director | 76,652 | $1.36M |
| Antoni Ribas | Director | 52,853 | $938.67K |
| Andrew J Perlman | Director | 48,325 | $858.25K |
| Patrick Machado | Director | 44,300 | $786.77K |
| Nicole Lambert | Director | 43,000 | $763.68K |
| Alexander Azoy | Chief Accounting Officer | 39,581 | $702.96K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RCUS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.